KNOWLEDGE BANK

Interviews

Digital Transformation in Pharma Manufacturing | David Holt, FactoryTalk | ISPE 2026 | Pharma Focus Asia

Group Executive Director, FactoryTalk
David Holt is the Group Managing Director at Factory Talk with extensive leadership experience across multiple industries He focuses on innovative software solutions that enable the digital transformation of operations within GxP pharmaceutical and medical deviceregulated industries

Articles

A Structured Review on BCRP-Mediated Multidrug Resistance

Many of the human ABC proteins are efflux transporters and three of them namely Pglycoprotein Pgp gene symbol ABCB the multidrug resistance protein MRP gene symbol ABCC and the breast cancer resistance protein BCRP gene symbol ABCG have been implicated to be the major efflux transporters responsible for multidrug resistance in cancer cells

Research Insights

Benchmarking Predictions of MHC Class I Restricted T Cell Epitopes in a Comprehensively Studied Model System

T cell epitope candidates are commonly identified using computational prediction tools in order to enable applications such as vaccine design cancer neoantigen identification development of diagnostics and removal of unwanted immune responses against protein therapeutics

Case Studies

Rapid, Comprehensive, And Aff Ordable Mycobacterial Diagnosis With Whole-genome Sequencing: A Prospective Case Study

Abstract Background Slow and cumbersome laboratory diagnostics for Mycobacterium tuberculosis complex MTBC risk delayed treatment and poor patient outcomes Wholegenome sequencing WGS could potentially provide a rapid and comprehensive diagnostic solution In this prospective study we compare realtime

Techno Trends

Encoded Therapeutics has Introduced ETX101 for the Treatment of Patients with Dravet Syndrome

Encoded Therapeutics has introduced ETX for the treatment of SCNA Dravet syndrome a rare and severe genetic neurological disorder that begins in early childhood

White Papers

Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches

In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS

TOP ARTICLES

1

Viksit Bharat@ 2047 envisioned the Indian Pharma Industry

Md. Faiyazuddin

Professor Md. Faiyazuddin, a distinguished academician with extensive experience working across the government, public and private sectors, sought to leverage his sixteen-year background in pharmacy education, product development, research consultation, and social pharmacy outreach activities in academia and industry. He is a Senior Professor and former Dean, R&D, Al-Karim University, who is lecturing on health and drug delivery research and holds visiting positions at prestigious universities in India and abroad. He has successfully completed research grants from various R&D agencies, such as SERB-DST and foreign agencies (DSR-UoH, DST, UiTM, Malaysia, Sick’s Children Hospital, Canada) worth Rs. 1.12 Million INR. With more than 120 research, conference, and review manuscripts, dozens of books and chapters, 15 accolades and awards, and various IPR have contributed greatly to the pharm fraternity of India. In addition to his daily job, Dr. Faiyazuddin has a keen interest in connecting researchers worldwide for practicing safe drugs under the flagship of the International Pharmaceutical Forum (a community of more than 250 pharma stalwarts across the globe).

 

Yogesh Subhash Chaudhari

Yogesh Subhash Chaudhari, a passionate educator at Dr L H Hiranandani College of Pharmacy, has contributed significantly to this field through research and review of papers in prestigious journals. His insights on AI for Pharmacist Newsletters on Linkedin are as follows.

 

2

Multi-Target Directed Ligands and Lipidomics Approach for Glioblastoma Drug Discovery

Dr. Stevan Pecic

Dr. Stevan Pecic is an assistant professor at the Department of Chemistry and Biochemistry at California State University, Fullerton. His main research interests and assignments are focused on the identification of novel inhibitors of enzymes involved in lipid metabolism and their evaluation as potential therapeutics in pain management.

 

Xiaohui Weng

Xiaohui Weng earned a bachelor’s in chemistry from Fordham University and recently completed her master’s degree working in Dr. Pecic medicinal chemistry lab at California State University, Fullerton. Her current research focuses on target identification for glioblastoma and the synthesis of new anti-cancer drugs.

 

Michael Gonzalez

Michael Gonzalez is a graduate student pursuing a master’s in chemistry at California State University Fullerton. Currently he also interns at a start-up biotech company, playing an important role in chemistry development for their high-throughput macrocyclic synthesis platform.

 

Arya Emami

Arya obtained his Hon. BSc. in Human kinetics from University of Guelph, where he completed a summer internship at Dr. Ghavami’s lab at University of Manitoba. Arya then pursued a double major from York University majoring in Neuropsychology. Arya’s research under the supervision of Dr. Ghavami resulted in four publications, and he has since been involved in the review and publication process of manuscripts in highly regarded journals. Arya is currently entering the second year of his Doctor of Dental Surgery program at the Faculty of Dentistry, University of Toronto.

Dr. Amir Barzegar Behrooz

Dr. Amir Barzegar Behrooz is a cancer researcher and postdoctoral fellow at the College of Pharmacy, University of Manitoba. His work focuses on various aspects of cancer biology, particularly glioblastoma. His work focuses on targeted cancer therapy, and theranostic targets in cancer cells via Onco-Multi-OMICS.

 

Dr. Rui Vitorino

Dr. Rui Vitorino, Principal Investigator at the University of Aveiro, specializes in OMICS, proteomics, and bioinformatics. His research on biofluids like saliva and urine aims to uncover disease pathways and biomarkers. Vitorino's multidisciplinary approach enhances early disease detection, influencing molecular and cell biology studies significantly.

 

Dr. Saeid Ghavami

Dr. Ghavami, an Associate Professor at the University of Manitoba, specializes in apoptosis, autophagy, and unfolded protein response regulation. With over 300 publications and numerous awards, he's globally recognised. Affiliated with institutions worldwide, he serves as Associate Editor for multiple scientific journals.

 

3

Artificial Intelligence - A current and future tool to learn chemical sciences

Ruchi Bharti

Ruchi Bharti received her M.Sc. from Patna University, in organic chemistry. PhD from National Institute of Technology Patna (NIT Patna), in 2012. There she worked on the development of new organocatalysts and their utilization in the synthesis of diverse heterocyclic compounds via multimulticomponent reactions. In 2017, she enrolled as assistant professor at R. P Sharma Institute of Technology, Since 2018, she joined Department of Chemistry, University Institute of Sciences, Chandigarh University, Punjab as Assistant Professor. Her recent research work is focused on the functionalisation of diverse heterocycles, multicomponent reactions, organocatalysis and their related biological and medicinal applications.

 

4

Reshaping the Clinical Trial Model

Anna Hayes

Anna Hayes is a senior data management leader (At Veramed) with nearly 20 years of experience in clinical research. She specializes in biometrics strategy, innovation, and operational excellence, driving smarter oversight and data-driven trial execution. Anna is passionate about integrating people, processes, and technology to future-proof clinical trials and elevate data quality.

5

Use of Steroids in COVID-19 patients

Anoop Kumar

Anoop Kumar currently working as Assistant Professor in Department of Pharmacology and Clinical Research, Delhi Pharmaceutical Sciences & Research University (DPSRU), New Delhi, India. He has authored more than 70 research and review articles and 10 book chapters in International Journal of repute. His research interests are Drug repurposing, Meta-analysis, Risk and benefit analysis of drugs and Pharmacoeconomic studies.

 

press releasesRead more...

Sino Biological Introduces AI-Trusted and Qualified Target Protein Collections for AI-Driven Discovery

As AI accelerates recombinant protein and antibody discovery for therapeutic and diagnostic development access to wellcharacterized target proteins is essential for evaluating AIdesigned molecules Sino Biological Inc Shenzhen Stock Exchange SZ a global biotechnology company

Collaboration aims to accelerate development of next generation medicines

The Personalised Medicine Centre PMC a joint initiative between Murdoch University and the Perron Institute biotechnology company Syngenis Labs and the Perron Institute are collaborating to establish a specialised preclinical safety testing platform for RNAbased medicines designed to treat diseases...

ITM and AtomVie Global Radiopharma Enter Supply Agreement for n.c.a. Lutetium-177

ITM Isotope Technologies Munich SE ITM a leading radiopharmaceutical biotech company and AtomVie Global Radiopharma AtomVie a radiopharmaceutical contract development and manufacturing organization CDMO today announced a supply agreement

Evotec and Bristol Myers Squibb advance strategic protein degradation partnership with second IND acceptance

Evotec SE NASDAQ EVO Frankfurt Prime Standard EVT today announced that its strategic protein degradation partnership with Bristol Myers Squibb has received a second Investigational New Drug IND acceptance from the US Food

Introducing Cognizant® Patient Hub Operations: AI-enabled patient access offering designed to shorten the path from prescription to therapy

Cognizant Nasdaq CTSH today introduced Cognizant Patient Hub Operations an offering built on NVIDIA accelerated computing that pairs AI agents with healthcareexperienced specialists to support patients and help drive better access to therapy

Thermo Fisher Scientific Launches Gibco™ VaxEvo™ CD 293 Medium to Advance Adenovirus Vaccine Production

Thermo Fisher Scientific the world leader in serving science today announced the Gibco VaxEvo CD Medium a chemically defined and animal originfree medium designed to support suspension HEK cell growth and hightiter adenovirus production

EventsRead more...

24 - 27

Nov 2026

Pharmtech & Ingredients 2026

Crocus Expo, Pavilion 2, Mosco...

24 - 25

Nov 2026

BioPharma Deals Conference 2026

Science Congress Center, Munic...

26 - 28

Nov 2026

One Health Conference 2026

Thapar Institute of Engineerin...

01 - 03

Dec 2026

Pharmaceutical Launch Excellence Summit

Novotel Amsterdam City, Nether...

01 - 03

Dec 2026

10th Antifibrotic Drug Development

Boston, MA at the Hotel Common...

02 - 04

Dec 2026

Genome Informatics 2026

Wellcome Genome Campus, UK

03 - 04

Dec 2026

03 - 04

Dec 2026

LATEST NEWSRead more...

Bionsight Enters into Collaboration with Astellas to Develop Autoimmune Disorder Therapy

Bionsight has entered into a global research and development RD collaboration with Astellas Pharma to explore a potential firstinclass treatment for autoimmune disorders

Isomorphic Labs Enters into Collaboration with MSD for Cancer Drug Discovery

Isomorphic Labs has entered into a strategic research collaboration with MSD to discover smallmolecule drug candidates for an important oncology target

Sanofi Receives Approval for Infilbray to Treat Neurological Symptoms of Type 3 Gaucher Disease

Sanofi has received approval from the US Food and Drug Administration FDA for Infilbray venglustat an oral medicine for treating neurological manifestations of Type Gaucher disease GD in adults and children weighing at least kg

Pfizer Enters into Agreement with Starna Therapeutics for Autoimmune Disease Treatments

Pfizer has entered into an exclusive licensing agreement with biotechnology company Starna Therapeutics to develop RNAbased in vivo chimeric antigen receptor Tcell CART therapies for autoimmune diseases

OXB Partners with Aura Biosciences for Drug Manufacturing

OXB has confirmed a manufacturing and supply partnership with Aura Biosciences

GSK Receives Approval for Nelkarmi to Treat Advanced ALK-Positive Lung Cancer

GSK plc LSENYSE GSK has received accelerated approval from the US Food and Drug Administration FDA for Nelkarmi neladalkib a treatment for adults with locally advanced or metastatic anaplastic lymphoma kinase ALKpositive nonsmall cell lung cancer NSCLC